Current state of treatment for primary cutaneous melanoma

Clinical and Experimental Medicine

Volumn 4, Issue 2, 2004, Pages 65-77

  Chung, E S ^a   Sabel, M S ^a,b   Sondak, V K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 3304 Cancer Center ^*  (United States)

Author keywords

Interferon; Melanoma; Sentinel lymph node biopsy; Vaccines

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; ESTRAMUSTINE; FOTEMUSTINE; GANGLIOSIDE GM2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNE TRANSFER FACTOR; INTERFERON; LEVAMISOLE; LOMUSTINE; MEGESTROL ACETATE; NITROSOUREA DERIVATIVE; PACLITAXEL; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 2; RETINOL; TAMOXIFEN; VINCA ALKALOID; VINCRISTINE;

CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOLERABILITY; EARLY DIAGNOSIS; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; LYMPHOMA; MEDICAL EDUCATION; MELANOMA; MORBIDITY; PATIENT EDUCATION; PERIODIC MEDICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MELANOMA; SKIN NEOPLASMS;

MYCOBACTERIUM BOVIS BCG; VINCA;

EID: 8644273902     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-004-0040-5     Document Type: Review

References (145)

1. Jemal A et al (2004) Cancer Statistics, 2004. CA Cancer J Clin 54:8
2. Balch CM et al (2001) Prognostic factors analysis of 17,600 melanoma aging system. J Clin Oncol 19:3622-3634
3. Essner R (2003) Surgical treatment of malignant melanoma. Surg Clin North Am 83:109-156
4. Chang AE, Johnson TM, Rees R (1997) Cutaneous neoplasms. In: Surgery: scientific principles and practice. Lippincott-Raven, Philadelphia, pp 2231-2246
5. Handley WS (1907) The pathology of melanotic growths in relation to their operative treatment. Lancet 1:927-933
6. Wong CK (1970) A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica 141:215-225
7. Kelly JW et al (1984) The frequency of local recurrence and microsatellites as a guide to re-excision margins for cutaneous malignant melanoma. Ann Surg 20:759-763
8. Santinami M et al (2001) Impact of clinical trials on the treatment of melanoma. Surg Oncol Clin North Am 10(4):935-947
9. Balch CM et al (1993) Efficacy of 2cm surgical margins for intermediate thickness melanomas (1 to 4mm): results of a multi-institutional randomized surgical trial. Ann Surg 218:262-267
10. Balch CM et al (2001) Long-term results of a prospective surgical trial comparing 2cm vs 4cm excision margins for 740 patients with 1-4mm melanomas. Ann Surg Oncol 8:101-108
11. Cohn-Cedermark G et al (2000) Long term results of a randomized study by the Swedish Melanoma Group on 2cm vs 5cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 89:1495-1501
12. Veronesi U et al (1988) Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 322:1159-1162
13. Morton DL et al (2003) Lymphatic mapping and sentnel lymphadenectomy for early-stage melanoma. Ann Surg 238:528-550
14. de Braud F et al (2003) Malignant melanoma. Oncol Hematol 47:35-63
15. Karakousis CP et al (1994) Groin dissection in malignant melanoma. Ann Surg Oncol 1:271-277
16. Balch CM, Cascinelli N, Milton GW (1985) Elective node dissection: pros and cons., in Cutaneous melanoma: clinical management and treatment results worldwide. Lippincott, Philadelphia, p 131
17. Balch CM (1988) The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 6:163-172
18. Cady B (1988) "Prophylactic"lymph node dissection in melanoma: does it help? J Clin Oncol 6:2-4
19. Veronesi U et al (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420-2430
20. Sim FH et al (1986) Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 61:697-705
21. Cascinelli N et al (1998) Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet 351:793-796
22. Balch CM et al (1996) Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Annals of Surgery 224:255-266
23. Balch CM et al (2000) Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol 7:87-97
24. Morton DL et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399
25. Morton DL et al (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453-463
26. Sabel MS et al (2000) Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center. Surgery 128:556-563
27. Thompson JF et al (1995) Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Research 5:255-260
28. Gershenwald JE et al (1998) Patters of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253-2260
29. Vuylsteke RJCLM et al (2003) Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: Long-term follow-up results. J Clin Oncol 21:1057-1065
30. Messina JL et al (1999) Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 23:689-690
31. Gershenwald JE et al (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983
32. Cascinelli N et al (2000) Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 7:469-474
33. Sondak VK, Taylor JM, Sabel MS et al (2004) Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11:247-258
34. Bleicher RJ et al (2003) Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 21:1326-1331
35. Morton DL et al (1991) Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patietns from the John Wayne Cancer Center. Ann Surg 244:491-499
36. Balch CM (2001) The revised melanoma staging system: its use in the design and interpretation of melanoma clinical trials. Am Soc Clin Oncol 244:491-499
37. - (2004) Melanoma: clinical practice guidelines in oncology. J Nat Comp Cancer Netw 2:46-60
38. Joseph E et al (1998) Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 5:119-125
39. Clary BM et al (2001) Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Annals of Surgery 233:250-258
40. Wagner JD et al (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462
41. Wagner JD et al (1999) Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Onc 6:398-404
42. Essner R et al (1999) Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 6(5):442-449
43. McMasters KM et al (2002) Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 9:137-1141
44. Morton DL et al (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter selective lymphadenectomy trial group. Ann Surg 230(4):453-463
45. Ballo MT, AK Kian (2003) Radiation therapy for malignant melanoma. Surg Clin N Am 83(2):323-342
46. Strom EA, MI Ross (1995) Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 2:445-449
47. Ballo MT et al (2003) Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97:1789-1796
48. Ballo MT et al (2002) Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Rad Oncol Biol Physiat 52:962-972
49. Creagan ET et al (1978) Adjuvant radiation therapy in the treatment of regional nodal metastases from malignant melanoma: a randomized prospective study. Cancer 42:2206-2210
50. Ridge JA (2000) Adjuvant radiation after lymph node dissection for melanoma. Ann Surg One 7:550-551
51. Meyskens Jr FL et al (1994) Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: A Southwest Oncology Group study. J Clin Oncol 12:2060-2065
52. Creagan ET et al (1989) A prospective, ramdomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 12:152
53. Markovic S et al (2002) Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol 25:552-556
54. Veronesi U et al (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913-916
55. Lejeune FJ et al (1988) An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761. Eur J Cancer Clin Oncol 24[Suppl 2]:S81-S90
56. Hill GJ et al (1981) DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjvuant Study COG protocol 7040. Cancer 47:2556-2562
57. Karakousis CP, Emrich EJ (1987) Adjuvant treatment of maligant melanoma with DTIC + Estracyt or BCG. J Surg Onc 36:235-238
58. Karakousis CP, Blumenson L (1993) Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur J Cancer 29A: 1831-1835
59. Hansson J et al (1985) Adjuvant chemotherapy ofmalignant melanoma. A pilot study. Am J Clin Oncol 8:47-50
60. Jacquillat C et al (1979) Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV or V. Recent Results Cancer Res 68:346-358
61. Tranum BL et al (1987) Lack of benefit of adjuvantive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. Cancer Treat Res 71:643-644
62. Quirt IC et al (1983) Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 128:929-933
63. Cunningham TJ et al (1979) A controlled ECOG study of adjuvant therapy in patients with stage I & II malignant melanoma. In: Adjuvant therapy of cancer II Salmon SE (ed) Grune and Stratton, New York, p 507
64. Wood WC et al (1978) Randomized trial of adjuvant therapy for 'high risk' primary malignant melanoma. Surgery 83:677-681
65. Knost JA et al (1982) Adjuvant chemoimmunotherapy for stage I/II malignant melanoma. J Surg Oncol 19:165-170
66. Sterchi JM et al (1985) A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and II cutaneous melanoma: an interim report. Cancer 55:707-712
67. Castel T et al (1991) Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica 183:25-30
68. McClay EF et al (2000) The effect of tamoxifen and cis-platin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer 83:16-21
69. McClay EF et al (2001) A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Research 11:309-313
70. Morton DL et al (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158-164
71. Morton DL et al (1974) BCG Immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:635-643
72. Sondak VK, Wolfe JA (1997) Adjuvant therapy for melanoma. Curr Opin Oncol 9:189-204
73. Ariyan S et al (1982) Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 92:459-463
74. Balch CM et al (1982) A randomized prospective clinical trial of adjuvant C parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): prognostic factors and preliminary results of immunotherapy. Cancer 49:1079-1084
75. Thatcher N et al (1986) Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. Br J Surg 73:111-115
76. Lipton A et al (1983) Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 51(1):57-60
77. Lipton A et al (1991) Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 9:1151-1156
78. Quirt IC et al (1991) Improved Survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 9:729-735
79. Spitler LE (1991) A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 9:736-740
80. Loutfi A et al (1987) Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 10:325-328
81. Ahmed FY et al (1996) A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Br J Cancer 74:1109-1113
82. Creagan ET et al (1997) Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. Am J Clin Oncol 20:490-492
83. Lawrence HS (1955) The transfer in humans of delayed skin sensitivity to streptococcal M stubstance and to tuberculin with disrupted leukocytes. J Clin Invest 34:219-230
84. Spitler LE, Levin AS, Wybran J (1976) Combined Immunotherapy in Malignant Melanoma. Cell Immunol 12:1-19
85. Gonzalez RL, P Wong, LE Spitler (1980) Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung. Cancer 45:57-63
86. Miller LL et al (1988) A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 61:1543-1549
87. Bukowski RM et al (1983) Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 51:269-272
88. Spitler LE, Grossbard ML, Ernstoff MS et al (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18:1614-1621
89. Lawson DH, Kirkwood JM (2000) Granulocyte-macrophage colony stimulating factor: another cytokine with adjuvant therapeutic beneift in melanoma? J Clin Oncol 18:1603-1605
90. Bart RS, Porzio NR, Kopf AW (1980) Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res 40:614-619
91. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818-1825
92. Kokoschka EM et al (1990) Long-term adjuvant therapy of high risk malignant melanoma with interferon a2b. J Invest Dermatol 95:8193-8197
93. Cascinelli N et al (1994) Results of adjuvant interferon study in WHO melanoma programme (letter). Lancet 343:913-914
94. Cascinelli N (1994) Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 14:410
95. Creagan ET et al (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alpha-2a in selected patients with malignant melanoma. J Clin Oncol, 13:2776-2783
96. Pehamberger H et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425-1429
97. Grob JJ et al (1998) Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905-1910
98. Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer. Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22(1):53-61
99. Kirkwood JM et al (1996) Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
100. Kirkwood JM et al (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458
101. Livingston, PO et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044
102. Kirkwood JM et al (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380
103. Kirkwood JM et al (2004) A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670-1677
104. Schallreuter KU et al (1991) Local treatment of cutaneous and subcutaneous metastatic melanoma with fotemusine. Cancer Chemother Pharmacol 29:167-171
105. Heller R et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83:148-157
106. Oratz R et al (2003) Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 13:59-66
107. Radny P et al (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. British Journal of Cancer 89:1620-1626
108. von Wussow P et al (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61:1071-1074
109. Vasquerano JE et al (1999) Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol 135:1276-1277
110. Si Z, Hersey P, Coates AS (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6:247-255
111. Kian AK et al (1998) Radiotherapy for melanoma. In: Soon S-J (ed) Cutaneous melanoma. Quality Medical Publishing, St. Louis, pp 389-403
112. Sauze WT et al (1991) Fraction size in extenal beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20:419-432
113. Sabel MS, Kraybill WG (2001) Perfusion Therapy. In: Perry MC (ed) Chemotherapy sourcebook. Lippincott Williams and Wilkins, Baltimore
114. Lens MB, Dawes M (2003) Isolated limb perfusion with melaphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 4(6):359-364
115. Fraker DL (1998) Hypertermic regional perfusion for melanoma of the limbs. In: Soon S-J (ed) Cutaneous melanoma. Quality Medical Publishing, St. Louis, pp 281-300
116. Thompson JF et al (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin in Surg Oncol 14:238-247
117. Lindner P et al (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Onc 9(2):127-136
118. Byrstyn, JC et al (1992) Relationship between immune response to melanoma vaccine immunization and clinical out-come in stage III malignant melanoma. Cancer 69:1157-1164
119. Byrstyn, JC et al (2001) Double blind trial of a polyvalent shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882-1887
120. Tai T et al (1985) Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612
121. Livingston PO et al (1989) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050
122. Takahashi T et al (1995) IgM antibodies to ganglioside GM3 and GD3 induced by active immunization correlated with survival in melanoma patients. Proc Am Assoc Cancer Res 36:485
123. Hersey P (1991) Ganglioside antigens in tissue sections of skin, naevi and melanoma: implications for treatment of melanoma. Cancer Treat Res 54:137-151
124. Helling F et al (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788
125. Chapman BP et al (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-KLH+QS21 vaccine: a dose-response study. Clin Cancer Res 6:874-879
126. Berd D, Maguire HC Jr., Mastrangelo MJ (1993) Treatment of human melanoma with a hapten modified autologous vaccine. Ann NY Acad Sci, 690:147-152
127. Berd D et al (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-2370
128. Berd D et al (1998) Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 25:646-653
129. Takahashi T et al (1999) IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol, 112:205-209
130. Morton DL et al (1992) Prolongation of survival in metastatic melanoma after specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482
131. Morton DL, A Barth (1996) Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244
132. Chan AD, DL Morton (1998) Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25:611-622
133. Di Fronzo LA et al (2002) Enhanced humoral immune respones correlates wtih improved disease-free and overall survival in AJCC stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242-3248
134. Hsueh EC et al (2002) Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 9:486-492
135. Morton DL (2001) Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma. Tumori 87:S57-S59
136. Takahashi T et al (1999) IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112:205-209
137. Hsueh EC et al (1998) Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol 5:595-602
138. Morton DL et al (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resecton of melanoma metastatic to regional lymph nodes. Ann Surg 236(4):438-449
139. Mitchell MS et al (1992) Active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164
140. Mitchell MS (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623-635
141. Mitchell MS et al (1993) Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action. Ann NY Acad Sci 690:153-166
142. Mitchell MS, Harel W, Groshen SG (1992) Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164
143. Mitchell MS, Von Eschen KB (1997) Phase III trial of Melacine melanoma vaccine versus combination chemotherapy in the treatment of stage IV melanoma (abstract). Proc Ame Soc of Clin Oncol 16:1778
144. Sondak VK et al (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20:2058-2066
145. Sosman JA et al (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075